SRC and non-small cell lung carcinoma: The natural compound deguelin, as a potential antimetastatic drug in non-small cell lung cancer, exerts its antimetastatic effect by inhibiting FAK/Src/paxillin signaling by inhibiting the expression of cathepsin Z and its interaction with integrin β3 [178].